Head to head
Takeda Pharmaceutical vs Teva Pharmaceutical Industries
Side-by-side on the measures that matter, with a plain-English read. Full detail: TAK · TEVA
TAK
Takeda Pharmaceutical
18.37+1.49%
1-year price shape — +29% over the period
Quant Rating C · 70/100
vs
TEVA
Teva Pharmaceutical Industries
39.18+0.13%
1-year price shape — +95% over the period
Quant Rating B · 93/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical pays the highest dividend yield.
| TAK | TEVA | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Drug Manufacturers - Specialty & Generic |
| Last price | 18.37 | 39.18 |
| Change today | +1.49% | +0.13% |
| 1-year return | +29.2% | +95.2% |
| Market cap | $58.68B | $45.70B |
| 52-week range | 12.77 – 19.10 | 18.83 – 40.79 |
| Valuation | ||
| P/E (TTM) | -55.67 | 65.30 |
| P/E percentile, own 5-yr range | 4th | 100th |
| P/B | 1.23 | 5.89 |
| Dividend yield | 3.26% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -0.31 | 1.21 |
| Net profit (TTM) | $-977.54M | $1.41B |
| Revenue (TTM) | $4.62T | $17.31B |
| Revenue growth (YoY) | +10.2% | -0.8% |
| Gross margin | 65.5% | 52.5% |
| Operating margin | 10.4% | 18.7% |
| Net margin | -3.5% | 4.1% |
| Free cash flow (TTM) | $626.68B | $1.35B |
| Ownership & sentiment | ||
| Institutional ownership | 51.5% | 77.5% |
| Insider activity (12mo) | 22 buy / 28 sell | 26 buy / 24 sell |
| Short interest (% of float) | 0.1% | 2.7% |
| Analyst consensus | 100% buy (1) | 100% buy (4) |
| Analyst price target | $43 (+134%) | $45 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | C (70) | B (93) |
| Company | ||
| Employees | 47,029 | 33,950 |
| Founded | 1781 | 1901 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.